News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Egetis comments on market rumors

March 30, 2023

Stockholm, Sweden, March 30, 2023. In light of existing rumors in the market the Board of Directors of Egetis Therapeutics AB (publ) (STO: EGTX) wishes to make the following statement:
Egetis Therapeutics has ongoing discussions with certain external parties regarding a potential acquisition of the company. There can be no certainty that a public take-over offer will be made, nor as to the terms of any such offer.



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10